Maribavir Reduces Hospital Stays for Transplant Patients with Cytomegalovirus Infections
May 13th 2022Phase 3 clinical trial data showed Takeda Pharmaceuticals’ antiviral drug maribavir (Livtencity) was superior to conventional antiviral treatment for clearing cytomegalovirus infections in transplant recipients.